IN2014KN01714A - - Google Patents
Info
- Publication number
- IN2014KN01714A IN2014KN01714A IN1714KON2014A IN2014KN01714A IN 2014KN01714 A IN2014KN01714 A IN 2014KN01714A IN 1714KON2014 A IN1714KON2014 A IN 1714KON2014A IN 2014KN01714 A IN2014KN01714 A IN 2014KN01714A
- Authority
- IN
- India
- Prior art keywords
- antibody
- cancer
- amino acid
- acid sequence
- seq
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 abstract 4
- 201000011510 cancer Diseases 0.000 abstract 4
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 3
- 239000012634 fragment Substances 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 102100029949 Caprin-1 Human genes 0.000 abstract 1
- 101710072528 Caprin-1 Proteins 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3015—Breast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012035342 | 2012-02-21 | ||
| PCT/JP2013/054312 WO2013125630A1 (ja) | 2012-02-21 | 2013-02-21 | 癌の治療及び／又は予防用医薬組成物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014KN01714A true IN2014KN01714A (cs) | 2015-10-23 |
Family
ID=49005808
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN1714KON2014 IN2014KN01714A (cs) | 2012-02-21 | 2013-02-21 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US9260513B2 (cs) |
| EP (1) | EP2818481B1 (cs) |
| JP (1) | JP6187257B2 (cs) |
| KR (1) | KR102005308B1 (cs) |
| CN (1) | CN104114581B (cs) |
| AU (1) | AU2013223137B2 (cs) |
| BR (1) | BR112014021099A2 (cs) |
| CA (1) | CA2864999C (cs) |
| DK (1) | DK2818481T3 (cs) |
| ES (1) | ES2749672T3 (cs) |
| HU (1) | HUE046788T2 (cs) |
| IN (1) | IN2014KN01714A (cs) |
| MX (1) | MX363136B (cs) |
| PL (1) | PL2818481T3 (cs) |
| PT (1) | PT2818481T (cs) |
| RU (1) | RU2639522C2 (cs) |
| WO (1) | WO2013125630A1 (cs) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2322221T3 (pl) * | 2008-08-05 | 2015-01-30 | Toray Industries | Kompozycja farmaceutyczna do leczenia i zapobiegania raka |
| WO2010016527A1 (ja) | 2008-08-05 | 2010-02-11 | 東レ株式会社 | 癌の検出方法 |
| US8828398B2 (en) * | 2010-02-04 | 2014-09-09 | Toray Industries, Inc. | Pharmaceutical composition for treating and/or preventing cancer |
| AU2012290948B2 (en) | 2011-08-04 | 2017-05-25 | Toray Industries, Inc. | Method for detecting pancreatic cancer |
| EP2740489B1 (en) * | 2011-08-04 | 2016-10-05 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of pancreatic cancer |
| JP6187256B2 (ja) | 2012-02-21 | 2017-08-30 | 東レ株式会社 | 癌の治療及び／又は予防用医薬組成物 |
| RU2649802C2 (ru) | 2012-03-30 | 2018-04-04 | Торэй Индастриз, Инк. | Фармацевтическая композиция для лечения и/или предотвращения рака желчного пузыря |
| JP6107654B2 (ja) * | 2012-03-30 | 2017-04-05 | 東レ株式会社 | 肝臓癌の治療及び／又は予防用医薬組成物 |
| CA2879185C (en) | 2012-07-19 | 2021-08-24 | Toray Industries, Inc. | Method for detecting cancer |
| PT2876446T (pt) | 2012-07-19 | 2019-03-25 | Toray Industries | Método para deteção de cancro |
| PT3031826T (pt) | 2013-08-09 | 2019-01-18 | Toray Industries | Composição farmacêutica para o tratamento e/ou a prevenção do cancro |
| KR102726248B1 (ko) | 2016-07-07 | 2024-11-05 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | 항체-애쥬번트 접합체 |
| BR112019008335A2 (pt) | 2016-10-28 | 2020-01-28 | Toray Industries | conjugado de um anticorpo, composição farmacêutica e método para o tratamento e/ou a prevenção de um câncer |
| MX2020009862A (es) | 2018-03-30 | 2020-10-08 | Toray Industries | Composicion farmaceutica para el tratamiento y/o prevencion de cancer. |
| JP2022525594A (ja) | 2019-03-15 | 2022-05-18 | ボルト バイオセラピューティクス、インコーポレーテッド | Ｈｅｒ２を標的とする免疫結合体 |
| CA3142887A1 (en) | 2019-06-13 | 2020-12-17 | Bolt Biotherapeutics, Inc. | Aminobenzazepine compounds, immunoconjugates, and uses thereof |
| AU2020359446A1 (en) | 2019-09-30 | 2022-04-21 | Bolt Biotherapeutics, Inc. | Amide-linked, aminobenzazepine immunoconjugates, and uses thereof |
| AU2020369652A1 (en) | 2019-10-25 | 2022-05-12 | Bolt Biotherapeutics, Inc. | Thienoazepine immunoconjugates, and uses thereof |
| JP7715041B2 (ja) | 2020-03-12 | 2025-07-30 | 東レ株式会社 | 癌の治療及び／又は予防のための医薬品 |
| KR20220152318A (ko) * | 2020-03-12 | 2022-11-15 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방을 위한 의약품 |
| EP4119160A4 (en) * | 2020-03-12 | 2024-04-03 | Toray Industries, Inc. | MEDICINE FOR THE TREATMENT AND/OR PREVENTION OF CANCER |
| EP4119159A4 (en) | 2020-03-12 | 2024-03-27 | Toray Industries, Inc. | MEDICINE FOR THE TREATMENT AND/OR PREVENTION OF CANCER |
| CA3175277A1 (en) | 2020-03-12 | 2021-09-16 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
| EP4146282A1 (en) | 2020-05-08 | 2023-03-15 | Bolt Biotherapeutics, Inc. | Elastase-substrate, peptide linker immunoconjugates, and uses thereof |
| WO2022036101A1 (en) | 2020-08-13 | 2022-02-17 | Bolt Biotherapeutics, Inc. | Pyrazoloazepine immunoconjugates, and uses thereof |
| AU2022298240A1 (en) | 2021-06-23 | 2024-01-18 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
| KR20240024074A (ko) | 2021-06-23 | 2024-02-23 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방을 위한 의약품 |
| AU2022316644A1 (en) | 2021-07-27 | 2024-02-29 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
| WO2023008459A1 (ja) | 2021-07-27 | 2023-02-02 | 東レ株式会社 | 癌の治療及び／又は予防のための医薬品 |
| CA3227706A1 (en) | 2021-07-27 | 2023-02-02 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
| CN118119409A (zh) | 2021-09-03 | 2024-05-31 | 东丽株式会社 | 癌的治疗和/或预防用药物组合物 |
| JP2024539993A (ja) | 2021-10-29 | 2024-10-31 | ボルト バイオセラピューティクス、インコーポレーテッド | システイン変異抗体を含むｔｌｒアゴニスト免疫複合体、及びその使用 |
| KR20250031149A (ko) | 2022-06-30 | 2025-03-06 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방용 의약 조성물 |
| EP4578458A1 (en) | 2022-08-24 | 2025-07-02 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
| EP4578459A1 (en) | 2022-08-24 | 2025-07-02 | Toray Industries, Inc. | Pharmaceutical product for treatment and/or prevention of cancer |
| EP4578457A1 (en) | 2022-08-24 | 2025-07-02 | Toray Industries, Inc. | Pharmaceutical for treating and/or preventing cancer |
| WO2024048542A1 (ja) | 2022-08-30 | 2024-03-07 | 東レ株式会社 | 癌の治療及び／又は予防のための医薬品 |
| KR20250053841A (ko) | 2022-08-30 | 2025-04-22 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방을 위한 의약품 |
| EP4640235A1 (en) | 2022-12-23 | 2025-10-29 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
| CN120981252A (zh) | 2023-02-14 | 2025-11-18 | 博尔特生物治疗药物有限公司 | 氮杂-苯并氮杂䓬免疫缀合物及其用途 |
| WO2024186626A1 (en) | 2023-03-03 | 2024-09-12 | Bolt Biotherapeutics, Inc. | Aza-bicyclic sting agonist immunoconjugates, and uses thereof |
| WO2025058000A1 (ja) * | 2023-09-13 | 2025-03-20 | 東レ株式会社 | 癌の治療、予防及び／又は診断用医薬組成物 |
Family Cites Families (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| WO1996002576A1 (en) | 1994-07-13 | 1996-02-01 | Chugai Seiyaku Kabushiki Kaisha | Reconstituted human antibody against human interleukin-8 |
| US5698396A (en) | 1995-06-07 | 1997-12-16 | Ludwig Institute For Cancer Research | Method for identifying auto-immunoreactive substances from a subject |
| WO2001032910A2 (en) | 1999-10-29 | 2001-05-10 | Human Genome Sciences, Inc. | 27 human secreted proteins |
| FR2761994B1 (fr) | 1997-04-11 | 1999-06-18 | Centre Nat Rech Scient | Preparation de recepteurs membranaires a partir de baculovirus extracellulaires |
| JP3998419B2 (ja) | 1998-04-03 | 2007-10-24 | 中外製薬株式会社 | ヒト組織因子（ｔｆ）に対するヒト型化抗体およびヒト型化抗体の作製方法 |
| US20030118599A1 (en) | 1999-04-02 | 2003-06-26 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
| EP1870466A3 (en) | 1998-07-14 | 2008-03-19 | Corixa Corporation | Compositions and methods for therapy and diagnosis of prostate cancer |
| RU2234942C2 (ru) | 1998-07-14 | 2004-08-27 | Корикса Корпорейшн | Выделенный опухолевый полипептид предстательной железы и кодирующий его полинуклеотид |
| US6969518B2 (en) | 1998-12-28 | 2005-11-29 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of breast cancer |
| US6335170B1 (en) | 1999-02-22 | 2002-01-01 | Torben F. Orntoft | Gene expression in bladder tumors |
| EP1187915A2 (en) | 1999-04-02 | 2002-03-20 | Corixa Corporation | Compounds for therapy and diagnosis of lung cancer and methods for their use |
| US6444425B1 (en) | 1999-04-02 | 2002-09-03 | Corixa Corporation | Compounds for therapy and diagnosis of lung cancer and methods for their use |
| US6949245B1 (en) | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
| US20020006404A1 (en) | 1999-11-08 | 2002-01-17 | Idec Pharmaceuticals Corporation | Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications |
| CZ20023567A3 (cs) | 2000-03-29 | 2003-11-12 | Corixa Corporation | Sloučeniny a způsoby pro terapii a diagnostiku karcinomu plic |
| AU3942202A (en) | 2000-11-30 | 2002-06-11 | Medarex Inc | Transgenic transchromosomal rodents for making human antibodies |
| US7919467B2 (en) | 2000-12-04 | 2011-04-05 | Immunotope, Inc. | Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
| US20040029114A1 (en) | 2001-01-24 | 2004-02-12 | Eos Technology, Inc. | Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer |
| RU2306952C2 (ru) | 2001-01-31 | 2007-09-27 | Байоджен Айдек Инк. | Лечение в-клеточных злокачественных опухолей с использованием комбинации применений, связанных с антителами, уменьшающими количество b-клеток, и с иммуномодулирующими антителами |
| AU2002311787A1 (en) | 2001-03-28 | 2002-10-15 | Zycos Inc. | Translational profiling |
| WO2002083070A2 (en) | 2001-04-10 | 2002-10-24 | Corixa Corporation | Compounds for immunotherapy and diagnosis of colon cancer and methods for their use |
| DE60227067D1 (de) | 2001-05-11 | 2008-07-24 | Kirin Pharma Kk | Künstliches menschliches chromosom mit dem gen für die lambda-leichte kette menschlicher antikörper |
| AU2002311909A1 (en) | 2001-05-11 | 2002-11-25 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
| US20030190640A1 (en) | 2001-05-31 | 2003-10-09 | Mary Faris | Genes expressed in prostate cancer |
| US20040142325A1 (en) | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
| JP2005535290A (ja) | 2002-02-22 | 2005-11-24 | ジェネンテック・インコーポレーテッド | 免疫関連疾患の治療のための組成物と方法 |
| US20050003390A1 (en) | 2002-05-17 | 2005-01-06 | Axenovich Sergey A. | Targets for controlling cellular growth and for diagnostic methods |
| US20040126379A1 (en) | 2002-08-21 | 2004-07-01 | Boehringer Ingelheim International Gmbh | Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and chemotherapeutic agents |
| EP2308968A1 (en) | 2002-11-26 | 2011-04-13 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| WO2004076682A2 (en) | 2003-02-26 | 2004-09-10 | Surromed, Inc. | Targets for controlling cellular growth and for diagnostic methods |
| AU2004235382A1 (en) | 2003-04-29 | 2004-11-11 | Wyeth | Methods for diagnosing AML and MDS differential gene expression |
| EP2003196A3 (en) | 2003-06-09 | 2009-01-07 | The Regents of the University of Michigan | Compositions and methods for treating and diagnosing cancer |
| US20070048738A1 (en) | 2003-07-14 | 2007-03-01 | Mayo Foundation For Medical Education And Research | Methods and compositions for diagnosis, staging and prognosis of prostate cancer |
| US20050032113A1 (en) | 2003-07-17 | 2005-02-10 | Mitsubishi Pharma Corporation | Membrane protein library for proteome analysis and method for preparing same |
| JP2008506352A (ja) | 2004-01-26 | 2008-03-06 | デビオビジョン・インコーポレーテッド | 新生物特異的ポリペプチド及びその使用 |
| AU2005224267B2 (en) | 2004-03-19 | 2011-07-21 | Imclone Llc | Human anti-epidermal growth factor receptor antibody |
| BRPI0509367A (pt) | 2004-03-30 | 2007-09-11 | Glaxo Group Ltd | anticorpo, fragmento de ligação de antìgeno, composição farmacêutica, métodos de tratar um paciente humano afligido com uma doença ou distúrbio, de triar um anticorpo, e de detectar hosm em uma amostra biológica, uso de um anticorpo terapêutico ou fragmento de ligação de antìgeno, medicamento, vetor, polunucleotìdeo, célula hospedeira recombinante estavelmente transformada ou transfectada, e, processo para a fabricação de um anticorpo terapêutico |
| WO2005100998A2 (en) | 2004-04-16 | 2005-10-27 | Europroteome Ag | Membrane markers for use in cancer diagnosis and therapy |
| WO2006002378A2 (en) | 2004-06-23 | 2006-01-05 | Avalon Pharmaceuticals | Determining cancer-linked genes and therapeutic targets using molecular cytogenetic methods |
| CN102580084B (zh) | 2005-01-21 | 2016-11-23 | 健泰科生物技术公司 | Her抗体的固定剂量给药 |
| CN101120252A (zh) | 2005-02-18 | 2008-02-06 | 儿童医疗中心有限公司 | 作为生物标记物用于上皮来源的癌症的诊断和预后的cyr61 |
| AU2006223374B2 (en) | 2005-03-11 | 2011-07-21 | Aspira Women’s Health Inc. | Biomarkers for ovarian cancer and endometrial cancer: hepcidin |
| JP2006316040A (ja) | 2005-05-13 | 2006-11-24 | Genentech Inc | Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法 |
| US8014957B2 (en) | 2005-12-15 | 2011-09-06 | Fred Hutchinson Cancer Research Center | Genes associated with progression and response in chronic myeloid leukemia and uses thereof |
| CA2642342A1 (en) | 2006-02-14 | 2007-08-23 | Dana-Farber Cancer Institute, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer |
| WO2008073162A2 (en) | 2006-08-17 | 2008-06-19 | Cell Signaling Technology, Inc. | Lysine acetylation sites |
| US20080107668A1 (en) | 2006-08-30 | 2008-05-08 | Immunotope, Inc. | Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
| US7615349B2 (en) | 2006-09-07 | 2009-11-10 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Melanoma gene signature |
| WO2008059252A2 (en) | 2006-11-15 | 2008-05-22 | Oxford Biomedica (Uk) Limited | Methods and composition fro t cell receptors which recognize 5t4 antigen |
| JP5663834B2 (ja) | 2008-03-14 | 2015-02-04 | 東ソー株式会社 | 遺伝子組換え抗体の製造方法 |
| TWI574698B (zh) | 2008-03-18 | 2017-03-21 | 建南德克公司 | 抗ｈｅｒ２抗體-藥物結合物及化療劑之組合及使用方法 |
| PL2322221T3 (pl) * | 2008-08-05 | 2015-01-30 | Toray Industries | Kompozycja farmaceutyczna do leczenia i zapobiegania raka |
| WO2010016527A1 (ja) | 2008-08-05 | 2010-02-11 | 東レ株式会社 | 癌の検出方法 |
| DK2324842T3 (da) | 2008-08-05 | 2015-06-22 | Toray Industries | Immunitetsinducerende middel |
| DK2467401T3 (en) | 2009-08-19 | 2017-03-20 | Merck Patent Gmbh | ANTIBODIES FOR THE DETECTION OF INTEGRIN COMPLEX IN FFPE MATERIAL |
| AU2010297580B2 (en) | 2009-09-22 | 2014-07-31 | Probiogen Ag | Process for producing molecules containing specialized glycan structures |
| RU2418587C1 (ru) * | 2010-01-21 | 2011-05-20 | Государственное образовательное учреждение высшего профессионального образования "Нижегородская государственная медицинская академия Федерального Агентства по здравоохранению и социальному развитию" (ГОУ ВПО "НижГМА Росздрава") | Способ лечения злокачественных опухолей головного мозга |
| JP5923985B2 (ja) * | 2010-02-04 | 2016-05-25 | 東レ株式会社 | 癌の治療及び／又は予防用医薬組成物 |
| BR112012018947B8 (pt) | 2010-02-04 | 2020-06-02 | Toray Industries | anticorpo anti-caprin-1 monoclonal, composição farmacêutica, combinação farmacêutica e usos de uma composição farmacêutica, de um anticorpo e de uma combinação farmacêutica |
| PL2532366T3 (pl) * | 2010-02-04 | 2017-02-28 | Toray Industries, Inc. | Kompozycja farmaceutyczna do leczenia i/lub zapobiegania nowotworowi |
| CN102822199B (zh) | 2010-02-04 | 2014-10-15 | 东丽株式会社 | 癌的治疗和/或预防用药物组合物 |
| AU2011211700B2 (en) * | 2010-02-04 | 2015-06-11 | Toray Industries, Inc. | Medicament for treating and/or preventing cancer |
| US8828398B2 (en) | 2010-02-04 | 2014-09-09 | Toray Industries, Inc. | Pharmaceutical composition for treating and/or preventing cancer |
| WO2012005550A2 (ko) | 2010-07-08 | 2012-01-12 | 강원대학교산학협력단 | 담낭암 치료용 약제학적 조성물 및 이를 이용한 담낭암의 성장, 전이 억제 및 치료 방법 |
| EA028515B1 (ru) | 2010-07-26 | 2017-11-30 | Ле Лаборатуар Сервье | Способы и композиции для терапии рака печени |
| JP5545105B2 (ja) | 2010-08-04 | 2014-07-09 | 株式会社ジェイテクト | トロイダル型無段変速機のディスクの研磨方法およびトロイダル無段変速機のディスクの研磨装置 |
| US9273128B2 (en) | 2011-08-04 | 2016-03-01 | Toray Industries, Inc | Pharmaceutical composition for treatment and/or prophylaxis of cancer |
| EP2740489B1 (en) | 2011-08-04 | 2016-10-05 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of pancreatic cancer |
| AU2012290948B2 (en) * | 2011-08-04 | 2017-05-25 | Toray Industries, Inc. | Method for detecting pancreatic cancer |
| RU2649802C2 (ru) * | 2012-03-30 | 2018-04-04 | Торэй Индастриз, Инк. | Фармацевтическая композиция для лечения и/или предотвращения рака желчного пузыря |
| JP6107654B2 (ja) * | 2012-03-30 | 2017-04-05 | 東レ株式会社 | 肝臓癌の治療及び／又は予防用医薬組成物 |
-
2013
- 2013-02-21 BR BR112014021099-3A patent/BR112014021099A2/pt not_active Application Discontinuation
- 2013-02-21 US US14/379,868 patent/US9260513B2/en active Active
- 2013-02-21 AU AU2013223137A patent/AU2013223137B2/en active Active
- 2013-02-21 WO PCT/JP2013/054312 patent/WO2013125630A1/ja not_active Ceased
- 2013-02-21 ES ES13751159T patent/ES2749672T3/es active Active
- 2013-02-21 HU HUE13751159A patent/HUE046788T2/hu unknown
- 2013-02-21 IN IN1714KON2014 patent/IN2014KN01714A/en unknown
- 2013-02-21 DK DK13751159.8T patent/DK2818481T3/da active
- 2013-02-21 CA CA2864999A patent/CA2864999C/en active Active
- 2013-02-21 PL PL13751159T patent/PL2818481T3/pl unknown
- 2013-02-21 PT PT137511598T patent/PT2818481T/pt unknown
- 2013-02-21 CN CN201380009166.3A patent/CN104114581B/zh active Active
- 2013-02-21 MX MX2014009747A patent/MX363136B/es unknown
- 2013-02-21 EP EP13751159.8A patent/EP2818481B1/en active Active
- 2013-02-21 KR KR1020147020831A patent/KR102005308B1/ko active Active
- 2013-02-21 RU RU2014138039A patent/RU2639522C2/ru active
- 2013-02-21 JP JP2013512279A patent/JP6187257B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| MX2014009747A (es) | 2014-11-14 |
| HUE046788T2 (hu) | 2020-03-30 |
| DK2818481T3 (da) | 2019-10-14 |
| US9260513B2 (en) | 2016-02-16 |
| RU2639522C2 (ru) | 2017-12-21 |
| CN104114581A (zh) | 2014-10-22 |
| EP2818481A4 (en) | 2015-10-07 |
| EP2818481B1 (en) | 2019-08-07 |
| MX363136B (es) | 2019-03-12 |
| RU2014138039A (ru) | 2016-04-10 |
| US20150044221A1 (en) | 2015-02-12 |
| JP6187257B2 (ja) | 2017-08-30 |
| WO2013125630A1 (ja) | 2013-08-29 |
| EP2818481A1 (en) | 2014-12-31 |
| AU2013223137A1 (en) | 2014-09-11 |
| CN104114581B (zh) | 2018-11-30 |
| KR102005308B1 (ko) | 2019-07-30 |
| CA2864999A1 (en) | 2013-08-29 |
| BR112014021099A2 (pt) | 2020-12-01 |
| CA2864999C (en) | 2020-06-30 |
| ES2749672T3 (es) | 2020-03-23 |
| PT2818481T (pt) | 2019-10-25 |
| AU2013223137B2 (en) | 2017-10-19 |
| KR20140130670A (ko) | 2014-11-11 |
| PL2818481T3 (pl) | 2020-02-28 |
| JPWO2013125630A1 (ja) | 2015-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014KN01713A (cs) | ||
| IN2014KN01714A (cs) | ||
| IN2014KN01716A (cs) | ||
| IN2014KN01715A (cs) | ||
| MX2014001375A (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| MX2014001372A (es) | Composicion farmaceutica para el tratamiento y/o prevencion de cancer pancreatico. | |
| MX2012008999A (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| MX2012008998A (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| MX342291B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| MX340016B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| MX360671B (es) | Composición farmacéutica para el tratamiento y/o prevención del cáncer. | |
| WO2017009843A3 (en) | Compositions, articles of manufacture and methods for treating cancer | |
| NZ713461A (en) | Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer | |
| NZ761006A (en) | Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema | |
| MX357965B (es) | Composicion farmaceutica para el tratamiento y/o prevencion de cancer de vesicula biliar. | |
| NZ705370A (en) | Fcγriib-specific fc region variant | |
| MY167232A (en) | Polypeptides binding to human complement c5 | |
| IN2014DN09963A (cs) | ||
| MX369195B (es) | Fragmentos mutantes de ospa y métodos y usos relacionados con estos. | |
| AR120721A2 (es) | Péptidos y composiciones para el tratamiento de daño articular | |
| EA201790341A1 (ru) | Анти-ск8 антитела для применения в лечении рака | |
| GB201118201D0 (en) | Novel peptides | |
| EA201590601A1 (ru) | Применение pedf-производных полипептидов для лечения остеоартрита | |
| WO2014039074A3 (en) | Therapeutic compositions and related methods | |
| MX362058B (es) | Péptido pntx(19) sintético, composición farmacéutica y uso. |